“The market is rewarding profitability, not upside value. … When there is [an IPO] window, we are prepared to go through it.”
— Cellomics President and CEO D. Lansing Taylor, on laying off 50 employees and the company’s IPO potential
Find “Cellomics Cuts One in Four Jobs as It Struggles to Become Profitable” by searching: Cellomics
Cracking the Rice Grain
Scientists in China have made public a sequence of a widely grown rice strain never before sequenced. The results of the indica strain sequence, presented to a genomic conference in San Diego by the Beijing Genomics Institute, marks a milestone for plant-genomics research.
Find “Chinese Team Makes Public Novel Rice Genome Sequence” by searching: rice genome
Let’s Call the Whole Thing Off
Powerful opposition from at least two influential institutional holders of Pharmacopeia stock ultimately led Pharmacopeia and Eos Biotechnology to nix their planned merger. David Martin, president and CEO of Eos, said, “We will continue to move forward aggressively with our plans for other therapeutic candidates and look to partner when appropriate.”
Find “Pharmacopeia and Eos Call Off Merger” by searching: Pharmacopeia
Graffinity Pharmaceuticals of Germany is using microarrays with small-molecule, drug-like compounds to provide drug target screening services for pharmaceutical and biotech companies. These new arrays may be an alternative to high-throughput screening for ligands that bind to potential protein drug targets.
Find “Graffinity Rides New Chemical Genomics Wave Using Small Molecule” by searching: Graffinity
A new assembly program from the Whitehead Institute called Arachne may give researchers outside of Celera Genomics their first chance at assembling whole-genome shotgun sequence. Only Celera’s assembler has been able to handle large and complex eukaryotic genomes so far, making Arachne the first publicly available tool for the job.
Find “Whitehead’s Arachne Brings Whole-Genome Shotgun Sequence Assembly to the Masses” by searching: Arachne
Game, Set, Mismatch
Cellzome and MDS Proteomics recently unveiled their technologies for large-scale analysis of cellular protein complexes. When the two data sets were scrutinized, one analysis found that only 20 percent of the yeast proteins identified overlapped, highlighting a potential pitfall for researchers hoping that new high-throughput analyses will immediately offer an accurate picture of a proteome — be it yeast or human.
Find “MDS and Cellzome Interaction Data Don’t Match: Are Standards a Solution?” by searching: Cellzome